FDA Files Lawsuit Against Vape Junkie Ejuice for Unauthorized E-cigarette Sales

Regulations by 2FIRSTS.ai
Dec.05.2023
FDA Files Lawsuit Against Vape Junkie Ejuice for Unauthorized E-cigarette Sales
FDA files permanent injunction lawsuit against Vape Junkie Ejuice for unauthorized production and distribution of e-cigarette products.

According to a statement released by the US Food and Drug Administration (FDA) on December 4th, the FDA has filed a lawsuit through the US Department of Justice (DOJ) against e-cigarette liquid retailer Vape Junkie Ejuice, seeking a permanent injunction. The reason for the legal action is their production, sale, and distribution of unauthorized e-cigarette products.

FDA Files Lawsuit Against Vape Junkie Ejuice for Unauthorized E-cigarette Sales
Image source: 2FIRSTS

 

This case marks the FDA's seventh initiation of a ban enforcement procedure to carry out the pre-market review requirements of the Federal Food, Drug, and Cosmetic Act (FD&C Act) pertaining to novel tobacco products.

 

The FDA reports that despite issuing a warning to Vape Junkie Ejuice and threatening potential further actions, including a ban, the company continues to illicitly produce, sell, and distribute unauthorized e-cigarette products to consumers.

 

In response to this issue, Brian King, the Director of the Center for Tobacco Products (CTP) at the FDA, stated:

 

The FDA is very clear that we will not tolerate individuals openly disregarding the law, especially after being warned.

 

Currently, the Department of Justice (DOJ) has filed a lawsuit on behalf of the Food and Drug Administration (FDA), seeking an injunction against Vape Junkie Ejuice. The lawsuit demands that Vape Junkie Ejuice cease the production, sale, and distribution of their e-cigarette liquid and obtain market authorization from the FDA before selling such products.

 

Ann Simoneau, Director of Compliance and Enforcement Office at CTP, stated:

 

The ban action today should serve as a clear reminder to all manufacturers that if they continue to sell illegal products, we will fully leverage the power of the law. The FDA is committed to collaborating with federal partners, including the Department of Justice, to enforce the law.

 

The FDA has announced that it has taken action against manufacturers, distributors, importers, and retailers of illegal e-cigarette products over the past year. As of November 2023, the FDA has issued approximately 640 warning letters to companies involved in the production and/or distribution of illegal e-cigarette products and devices. In addition, over 400 warning letters have been sent to retailers selling unauthorized e-cigarettes, and civil penalty complaints have been filed against 36 e-cigarette manufacturers and 42 retailers for manufacturing and/or selling unauthorized products.

 

Notice

1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.

2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.

3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.

Copyright

This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.

This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.